The immune system has a remarkable ability to respond to seemingly endless antigens. In essence, a productive immune response takes place along a well defined but treacherous line, that is to effectively eradicate pathogens, and at the same time avoid causing damage to self organs. This type of response is fine-tuned, at least in part, by a complex array of pathways that either promote or inhibit the activation of innate and adaptive immune cells. Much effort has been focused on pathways that can support immune activation. In this article, we review specifically pathways that can inhibit immune responses and maintain immune homeostasis, highlighting our recent understanding on the role of inhibitory receptors that selectively engage the self MHC class I molecules and the B7 superfamily members, we also discuss the inhibitory Fc receptors and inhibitory cytokines and how such pathways, either individually or collectively, regulate innate and adaptive immune responses. Finally, we summarize new emerging approaches on how such negative pathways can be therapeutically modulated in various disease settings.
Introduction
The immune system consists of an innate and an adaptive arm, and in most cases, cells in both arms conspire with one another to mediate robust and productive immunity. The innate immune cells such as DCs, NK cells, and macrophages provide the first line of defense when the system is confronted by pathogens, those cells are rapidly mobilized and activated upon antigen encounter, which subsequently result in the activation of adaptive immune cells including T cells and B cells (1) . It is the activation and prompt effector differentiation of adaptive immune cells that eventually lead to the complete elimination pathogens. Importantly, subsets of activated T cells and B cells also evolve into long-lived memory cells that provide long lasting immunity after the pathogens are cleared from the body (2) . Furthermore, other T cells become suppressor or regulatory cells that prevent excessive immune activation that may otherwise lead to tissue damage (3) . It is believed that regulatory cells achieve this effect by suppressing both innate and adaptive cells in the immune system. These opposing forces of activation and suppression are indispensable in immune homeostasis, and together they ensure both immunity and immune tolerance.
There is an incredibly complex array of cytokines, chemokines, toll-like receptors and costimulatory molecules involved in the initiation and progression of immune responses (4) . Equally complex is the diversity of pathways and mechanisms employed by the immune system to regulate and/or terminate ongoing immune responses in a timely fashion (Figure 1 ), as failure to do so will inevitably lead to disastrous consequences to the hosts. This notion has been unequivocally demonstrated by the development of autoimmune diseases under a variety of conditions in which the regulatory mechanisms somehow fail (5) . In this review article, we focus specifically on the inhibitory pathways that are critically involved in suppressing or terminating immune responses, and therefore maintaining normal immune homeostasis. We highlight the inhibitory receptors that bind to the autologous MHC class I ligands, the B7 family members as well as inhibitory Fc receptors and immune regulatory cytokines. Such inhibitory mechanisms span a wide spectrum of immune responses involving both innate and adaptive immune cells. Finally, we conclude by providing a summery on the emerging therapeutic interventions by targeting such inhibitory pathways in various disease settings.
The inhibitory receptors that use autologous MHC class I molecules as ligands represent a unique family of cell surface receptors, these inhibitory receptors are expressed primarily by NK cells, though subsets of T cells, especially CD8 + T cells, are believed to express some of such receptors (6) . There are two structurally distinct families of NK inhibitory receptors identified thus far, which include the killer immunoglobulin-like receptor (KIR) family and the C type lectin-like family (e.g. Ly49, NKG2A/B, CD94) (7). KIR receptors are type I transmembrane glycoproteins belonging to the Ig superfamily, such receptors are exclusively expressed by human NK cells, whereas mouse NK cells express the lectin-like Ly49 receptors, which are type II transmembrane glycoproteins. In both species, NK cells also express the heterodimeric CD94/NKG2A/B receptors on the cell surface (8) . There are at least 14 differentially expressed genes encoding the KIR receptors in humans, and such KIR receptors can be further divided into two different functional groups based on the number of Ig domains in the extracellular region and the length of their cytoplasmic region. Specifically, the long cytoplasmic region contains ITIM motif, thus transmitting inhibitory signals upon ligand binding, whereas those with short cytoplasmic domains lack the ITIM motif and often deliver activating signals to NK cells (9, 10) . Differences in their extracellular domains are believed to regulate differential bindings to their diverse ligands. In both humans and mice, the NK inhibitory receptors exhibit tremendous genetic and expression polymorphism, which contributes significantly to the functional diversity of NK cells.
The autologous MHC class I molecules are the predominant ligands for NK inhibitory receptors, though some MHC class I molecules can also engage NK activating receptors (11) . Earlier studies demonstrated that more than 90% of NK cells in the periphery express NK inhibitory receptors that selectively and specifically engage self MHC class I molecules. It is important to note that the polymorphic KIR receptors in humans (and Ly49 in mice) interact with diverse MHC class I molecules, which are also highly polymorphic. The CD94/NKG2A/B receptors preferentially bind to the relatively non-polymorphic HLA-E molecules in humans and Qa-1 molecules in mice. Thus, the inhibitory KIR and CD94/NKG2A/B receptors act together to establish an NK repertoire that relies on constitutive expression of autologous MHC class I molecules to achieve dominant suppression and self tolerance. At a molecular level, the identity and the number of NK inhibitory receptors expressed by individual NK cells are strikingly different. In addition, different NK inhibitory receptors also interact with diverse allotypic MHC class I molecules (7) . Thus, the combination of these effects creates a pool of NK cells that are extremely heterogeneous in vivo.
With (12, 13) . The exact mechanism by which NK inhibitory receptors confer effector function of NK cells remains incompletely defined, but it is an area of intense investigation. In the periphery, however, engagement of self class I molecules by the same NK inhibitory receptors confers potent suppression of fully matured NK cells and this suppression includes cytolytic and inflammatory functions of NK cells (9) . Thus, the MHC class I-mediated inhibition is the primary mechanism by which NK tolerance to self is induced and maintained.
Given the diversity of NK cells and their close association with other cell types in the immune system, the implication of NK tolerance endowed by self MHC class I-mediated suppression is significant. For example, cell types whose levels of MHC class I expression are low or absent may become easy targets of NK-mediated killing, as lack of inhibitory signals will relieve NK cells from dominant suppression (14) . Indeed, NK cells can readily kill virally infected or transformed autologous cells with down-regulated class I expression, thus acting as an important innate cell type in protective immunity and immune surveillance (15) . In fact, this property of NK cells has been actively exploited as a way to boost anti-tumor immunity (16) . In addition, NK cells are closely associated with DCs, and depending on the activation status and their levels of MHC class I expression, NK cells can either kill DCs (immature and low class I expression) or activate DCs, thus indirectly regulating immunity and immune homeostasis (11) . Moreover, in the transplant setting, mismatch for the MHC molecules between donor and recipient often results in the activation of NK cells (alloreactive NK cells), as the NK inhibitory receptors often fail to engage allogeneic MHC class I molecules, thus rendering NK cells highly cytolytic to allogeneic cells (17, 18) . In leukemia patients who undergo bone marrow transplantation, the impact of alloreactive NK cells on graft versus leukemia effect has been extensively studied in the clinic. It has been shown that transplant patients who bear donor bone marrow-derived NK cells that are alloreactive against host cells experience markedly reduced incidence of relapse as compared to those lacking alloreactive NK cells (19) . In solid organ transplants, host NK cells can readily kill graft derived allogeneic DCs, thereby reducing the priming of host alloreactive T cells, which is permissive to tolerance induction (17, 20) . Studies in this area suggest that beside the adaptive immune cells, NK cells can also be therapeutically targeted by modulating their receptor-ligand interactions.
Although most studies on the inhibitory MHCrecognizing receptors have focused on NK cells, there is compelling evidence that such inhibitory receptors may also modulate T cells. The inhibitory CD94/NKG2A heterodimers are expressed on a subset of CD8 + T cells, especially after activation, and inhibition of CD8 + T cell-mediated cytotoxicity has been reported in multiple studies (21) . In addition, expression of KIR inhibitory receptor by activated T cells has been associated with altered T-cell survival, impaired anti-tumor immunity, and autoantigen-induced peripheral T cell tolerance (22) . Thus, the MHC class I-binding inhibitory receptors may have a much broader impact on innate and adaptive immune cells.
Inhibitory receptors that engage B7 ligands
CTLA-4 and PD-1 are inhibitory receptors that utilize B7 family members as ligands; they belong to the Ig superfamily and are expressed predominantly by activated T cells. The ligands for CTLA-4 are B7-1 (CD80) and B7-2 (CD86), which are preferentially expressed by APCs. B7-1 and B7-2 also interact with CD28 to deliver costimulatory signals to T cells. Thus, B7 molecules can trigger either costimulatory signals or coinhibitory signals depending on whether they engage CD28 or CTLA-4 (23). PD-1 has at least two known ligands, PD-L1 and PD-L2, both of which are members of the B7 family. PD-L1 and PD-L2 exhibit a much broader expression pattern, and besides APCs, some parenchymal cells including vascular endothelial cells also express such ligands (24) . CTLA-4 and PD-1 are critical regulators in the immune system, playing a key role in down-regulating T cell activation as well as in maintaining T cell tolerance and immune homeostasis. The individual role of CTLA-4 and PD-1 is discussed in detail below.
CTLA-4
The role of CTLA-4 as a critical negative regulator has been extensively studied in multiple models. Initial studies showed that blocking CTLA-4 signaling using an anti-CTLA4 mAb can markedly enhance T cell activation and effector differentiation in vitro when stimulated with antigen or polyclonal activator (e.g. anti-CD3) (25) . In addition, blocking CTLA-4 signaling also prevents the induction of peripheral tolerance in vivo including tolerance to organ transplants (26, 27) . Importantly, genetic deficiency of CTLA-4 (CTLA-4 −/− mice) results in the development of a massive lymphoproliferation leading to premature death of all animals (28) , and this striking phenotype firmly establishes CTLA-4 as a critical "master regulator" of immune activation (29) .
The precise mechanisms by which CTLA-4 inhibits T cell activation and effector functions remain incompletely defined. The cytoplasmic tail of CTLA-4 contains the ITIM motif, which has been shown to recruit signaling molecules that are involved in transmitting inhibitory signals (30) . In activated T cells, CTLA-4 is recruited to the micro-domains in the immune synapse, suggesting that CTLA-4 may inhibit TCR-mediated signaling events in activated T effector cells. Moreover, it has been reported that CTLA-4, upon engaging B7 ligands on APCs, induces the production of indoalamine 2,3-dioxygenase by APCs, an enzyme that breaks down tryptophan, which in turn inhibits T cell activation (31, 32) . Other mechanisms include competition for B7 ligands, which competitively prevents B7/CD28 costimulation, induction of anergy, and induction of apoptosis of activated T cells (33) . It should be noted that CTLA-4 is constitutively expressed on Foxp3 + Tregs, and therefore, Tregs may use CTLA-4 to mediate suppression of T effector cells. The recent finding that conditional deletion of CTLA-4 in Tregs, but not in other cell types, results in impaired Treg functions appears to support this notion (34) . Further studies demonstrate that Tregs seem to suppress the activation of DCs, which limit their ability to prime T effector cells during immune responses, and CTLA-4 is indispensable in Treg-mediated inactivation of DCs (34) .
The importance of CTLA-4 in negatively regulating immune responses attracts tremendous attention in therapeutic targeting of this pathway. In fact, blocking CTLA-4 negative signals has been extensively studied as an approach to boost anti-tumor immunity, and in certain models, blocking CTLA-4 can drastically enhance tumor rejection. On the other hand, preserving or stimulating CTLA-4 negative pathway is therapeutically important in tolerance induction in models of transplantation and autoimmunity (35, 36) . Some studies also suggest that variation in CTLA-4 expression or CTLA-4 polymorphism may be an important prognostic marker for certain autoimmune diseases including Graves' disease, autoimmune hypothyroidism and type 1 diabetes (37).
PD-1
As mentioned above, PD-1 is expressed on activated T cells, B cells and NK cells, suggesting that PD-1 may have a broad impact on both innate and adaptive immune cells. Studies using blocking mAbs against PD-1, PD-L1, and PD-L2 clearly demonstrate the importance of this pathway in inhibiting T cell activation and effector differentiation, both in vitro and in vivo (38) . In general, the inhibitory effect of PD-1 and the relative significance of PD-1/PD-L1 versus PD-1/PD-L2 pathway are often model-dependent. Moreover, the strength of TCR stimulation, presence or absence of CD28 costimulation and IL-2, and the involvement of CD4 + or CD8 + T cells also affect the inhibitory effect of the PD-1 pathway (24) . In addition, genetic mutations of PD-1 result in the development of autoimmune diseases in mice, and depending on their genetic background, the nature of disease and the disease severity are strikingly different. For example, PD-1 knockout mice on the C57BL/6 background develop lupus-like autoimmunity, whereas PD-1 knockout mice on the Balb/c background develop autoantibody-mediated cardiomyopathy (39, 40) . As compared to that of CTLA-4 knockout mice, autoimmune diseases in PD-1 knockout mice are delayed in onset, more limited, and also strain dependent. This difference suggests that CTLA-4 and PD-1, though both inhibit T cell activation, may regulate different aspects of immune activation.
PD-1/PD-L1/2 pathways have been shown to play a key role in models of transplantation, autoimmune diseases, graft versus host response and cancer immunity (41) (42) (43) BTLA in regulating other cell types besides T cells. It has been recently shown that CD160 also binds to HVEM, and similar to BTLA/HVEM interactions, CD160/HVEM engagement also delivers a potent negative signal that inhibits T cell activation. CD160 is a glycosylphosphatidylinositol-anchored molecule of the Ig superfamily and expressed on a subset of CD4 + T cells and CD8 + T cells. Importantly, cross-linking CD160 by HVEM strongly inhibits anti-CD3 and anti-CD28-induced T cell proliferation in vitro, and inhibition of CD4 + T cell proliferation by HVEM-transfected cells appears to be dependent on both CD160 and BTLA (50) . It should be noted that HVEM has another ligand called LIGHT, and HVEM/LIGHT engagement triggers a costimulatory signal. Thus, HVEM can trigger either a positive or negative signaling events depending on whether HVEM engages CD160/BTLA or LIGHT.
There are limited studies on the role of BTLA/CD160 pathways in vivo. In transplant models, the effect of BTLA on transplant outcome seems to depend on the degree of MHC mismatch between donor and recipient or interaction with other negative pathways such as PD-1. In fact, in a partial MHC class II mismatched heart transplant model (bm12 to B6), BTLA deficiency in the recipient, or BTLA blockade using a blocking mAb, induced prompt heart allograft rejection whereas WT recipients accepted the graft long-term (51) . However, the role of BTLA signaling on allograft survival in fully MHC mismatched transplant is less clear. Also, the potential interactions of BTLA/CD160 with other positive and negative costimulatory molecules in fine-tuning the nature of the allograft response remain to be determined.
Inhibitory Fc receptors
Fc receptors (FcRs) are widely expressed by immune cells, but most prominently on B cells, myeloid cells, NK cells, mast cells and neutrophils. The ligands for FcRs are the Fc portion (the constant region) of antibodies. Several different types of FcRs have been identified, primarily based on the Ig class (e.g. IgG, IgA, IgE, IgD) they interact with. Moreover, in a given type, for example, the FcRs that bind IgG (also called FcγR), there are multiple subtypes of FcRs that can selectively bind to different IgG isotypes (52) . Thus, the FcRs that can interact with Abs in vivo are extensive, and because of that, the impact of such interactions on immune responses is significant. It is well recognized that engagement of Abs with their FcRs mediates multiple effects, which include antibody-dependent and complement mediated cytotoxicity and complement-mediated inflammation, such engagement also mediates cellular activation or suppression depending on the types of FcRs engaged and the Ig class/isotypes involved (52) . Hence, FcRs play an important role in activation and regulation of antibody-mediated responses.
Studies in murine models have shown that among the FcRs, FcRIIB is a potent inhibitory receptor that plays a critical role in the suppression of antibody-mediated allergy and autoimmunity (53) , the inhibitory FcRIIB also counter-balances the activating signals transduced by other activating FcRs (54) . Thus, modulation of inhibitory and activating FcRs is therapeutically important in immune interventions. Mechanistically, the cytoplasmic tail of the FcRIIB contains an ITIM motif and engagement of FcRIIB by IgG induces the phosphorylation of ITIM at the tyrosine site, which then results in the recruitment and activation of SHIP-1 phosphotase. SHIP-1 dephosphorylates PI3 triphosphate that prevents the activation of Btk, PDK-1/2, and Akt kinases. This cascade of events leads to inhibition of cellular activation, proliferation, and sometimes induces apoptotic cell death (52) . Importantly, genetic mutations of FcRIIB in mice results in the development of prominent autoimmune diseases, further demonstrating an inhibitory role for FcRIIB in vivo (55) .
In humans, there are at least 6 FcRs for IgG (hFcRs) encoded by distinct genes and 3 of which have 2 or 3 polymorphic variants. The specificity and affinity of individual hFcRs for the 4 human IgG subclasses remain incompletely defined. It has been shown that the inhibitory receptor FcRIIB has a lower affinity for IgG1, IgG2, and IgG3 than all other hFcRs. Aggregation of FcRIIB on human peripheral IgM(+) B cells inhibits B cell proliferation and calcium influx triggered by BCR cross-linking, suggesting that FcRIIB could negatively regulate IgM(+) B cells before class-switch occurrence (52) . From a therapeutic standpoint, recent studies have demonstrated that stimulation of the inhibitory FcRIIB is critically involved in the beneficial effects of intravenous administration of Ig (IVIG) as a therapeutic modality in the clinic (56) .
Inhibitory cytokines
Cytokines are products of immune activation; they are critically involved in activation, proliferation, and effector differentiation of both innate and adaptive immune cells. However, some cytokines are also key regulators of immune responses, inhibiting activation of innate and adaptive cells and such cytokines include TGF-, IL-10 and IL-35. It is interesting that these inhibitory cytokines are also products of Foxp3+ Tregs. IL-10 is produced mainly by activated macrophages and monocytes as well as by Th2 cells, and the primary function of IL-10 seems to inhibit maturation of APCs and suppress Th1 differentiation (57) . However, this effect is not absolute, and in some models IL-10 can act as an immune stimulatory cytokine promoting effector differentiation of cytotoxic CD8+ T cells (58) . A critical role for IL-10 in negatively regulating immune activation is clearly established by the generation of IL-10 deficient mice. Genetic knockout of IL-10 consistently induced the development of autoimmune colitis (59), demonstrating an important role for IL-10 in suppressing autoimmunity.
TGF- is produced by a variety of cell types in vivo, and TGF- exists in two different forms: the soluble form and cell surface bound form (60) . TGF- has broad anti-proliferative and anti-inflammatory effects both in vitro and in vivo (61) . In the T cell compartment, it inhibits Th1/Th2 differentiation, and together with IL-2, it promotes the induction of Foxp3 + Tregs (62) . TGF- has also been shown to suppress the activation of NK cells, macrophages, and DCs (63) . In addition, TGF- is also used by Foxp3 + Tregs to mediated suppressive effects (64) . Thus, TGF- participates in immune regulation and immune homeostasis via several different mechanisms, and depending on the models and how the immune response is initiated, one mechanism may predominate another or different mechanisms may come into play at different time points following immune activation. Given the broad effects of TGF- in vivo, it is not surprising that TGF- deficient mice suffer from wide-spread tissue inflammation and die of young age (65) .
IL-35 is a newly identified cytokine and belongs to the IL-12 cytokine family. IL-35 is a heterodimeric protein consisting of a p35 subunit, which is a shared subunit with IL-12, and the EBI3 subunit (66) . The EBI3 is also a subunit of IL-27 (67 
Summary and future perspectives
Clearly, the immune system employs a variety of inhibitory mechanisms and pathways to control both innate and adaptive immune response as well as to ensure immune tolerance and immune homeostasis. In a broad sense, such inhibitory pathways appear to be highly specialized and compartmentalized. For example, NK cells are regulated by the autologous MHC class I-binding receptors; such receptors confer dominant suppression of NK cells upon binding to self MHC class I molecules. As NK cells are closely associated with DCs in vivo, NK cells can either kill or activate DCs, a process called "DC editing", and this process is strongly influenced by levels of MHC class I expression on DCs. Thus, the NK inhibitory receptors play an important role in regulating the activation of innate immune cells. Alone the same line, activation of macrophages can be inhibited by Sirp upon engaging its ligand CD47. On the other hand, CTLA-4, PD-1, BTLA and CD160 are critically involved in the suppression of T cells, and under some conditions the suppression of B cells. Moreover, regulation of B cell responses can be further strengthened by the inhibitory FcRs.
In addition, Foxp3 + Tregs, by acting as dominant regulators in the immune system, regulate a wide spectrum of innate and adaptive immune responses either by releasing immunosuppressive cytokines or by other unidentified mechanisms. Under specific conditions or in a defined model system, however, these diverse inhibitory pathways and mechanisms may actually interact with each other and then integrate into an overall regulatory circuit in vivo; this circuit not only ensures productive immunity but also controls immune tolerance and immune homeostasis. This complexity presents both opportunities and challenges in targeting these pathways in the treatment immune-mediated diseases. Clearly, development of clinically applicable strategies to harness the potency of inhibitory pathways for therapeutic purposes remains a major challenge for the future.
